Introduction {#s1}
============

Sudden Unexpected Death in Epilepsy (SUDEP) is the leading cause of premature mortality in patients with intractable epilepsy ([@B1]). The main SUDEP phenotype comprises frequent generalized convulsive seizures in patients with early onset, longstanding epilepsy ([@B2], [@B3]). Both cardiac and respiratory mechanisms likely contribute to SUDEP pathophysiology ([@B3], [@B4]), although video electroencephalogram monitored (VEEG) deaths suggest that terminal cardiac arrest is almost always preceded by central apnea ([@B5]). Central, obstructive and mixed apneas have all been proposed as SUDEP mechanisms, and may occur during or after seizures ([@B6]--[@B9]). Whereas, ictal central apnea (ICA) is common, prolonged ICA with profound oxygen desaturation may pose SUDEP risk, as may post-convulsive central apnea (PCCA) ([@B10]--[@B14]). The latter, when combined with bradycardia/asystole, comprised the majority of observed deaths in the MORTEMUS series, and two near-SUDEP instances in one observational SUDEP risk study ([@B14]). Thus, it is evident that breathing dysfunction plays a major role in SUDEP, although the exact characteristics of respiratory compromise that contribute to death are unknown ([@B15]). Since central apnea (prolonged ictal or post-convulsive) seems a viable, agonal mechanism, we set out to determine incidence, recurrence, and characteristics of peri-ictal central apnea. We assessed its influence on potential seizure severity biomarkers, such as hypoxemia extent and post-ictal generalized electroencephalographic (EEG) suppression (PGES) in a prospective study of SUDEP risk biomarkers. Further, we describe two additional cases of near-SUDEP due to prolonged, exaggerated peri-ictal central apnea.

Material And Methods {#s2}
====================

Patient Selection
-----------------

All patients were prospectively recruited participants in the NINDS Center for SUDEP Research\'s Autonomic and Imaging Biomarkers of SUDEP multi-center project (U01-NS090407), and its preliminary phase, the Prevention and Risk Identification of SUDEP Mortality (PRISM) Project (P20NS076965). This study was carried out in accordance with the recommendations of University Hospitals Case Medical Center Institutions Review Boards (UHIRB) and University of Iowa, School of Medicine, Iowa City (IA) Institutions Review Boards. The protocol was approved by UHIRB and University of Iowa, School of Medicine, Iowa City (IA) Institutions Review Boards. All subjects gave written informed consent in accordance with the Declaration of Helsinki. Informed written consent was obtained for publication of two clinical cases. Patients with intractable epilepsy (failure of adequate trials of two or more antiepileptic medications) ([@B16]) aged ≥18 years underwent video-electroencephalography (VEEG) evaluation in the adult epilepsy monitoring units (EMU) of participating centers from September 2011 until April 2018. We included patients with recorded electroencephalographic seizures with or without clinical correlate, who had complete polygraphic physiological recordings sufficient for analysis. Exclusion criteria were status epilepticus (SE), obscured or unavailable video, and insufficient multimodal physiological recording quality.

Demographic and clinical data were collected. Semiology was classified into two types ([@B17]). (1) Generalized convulsive seizures (GCS) which included generalized tonic-clonic seizures, focal to bilateral tonic-clonic seizures, and focal onset motor bilateral clonic seizures. (2) Non-convulsive seizures (NCS), which included seizures with focal onset without evolution to bilateral tonic-clonic seizures, myoclonic seizures, absence seizures, and electroencephalographic seizures without clinical correlate. We determined state (awake or asleep) at seizure onset. We defined the putative epileptogenic zone based on clinical history, seizure semiology, neuroimaging, and VEEG.

Data Collection
---------------

All patients underwent prolonged surface VEEG monitoring using the 10--20 International Electrode System. EEG and electrocardiogram (EKG) were acquired using Nihon Kohden (Tokyo, Japan), Micromed (Modigliani Veneto, Italy), and Xltek (Natus) acquisition platforms. Peripheral capillary oxygen saturation (SpO~2~) was monitored using pulse oximetry (Nellcor OxiMax N-600x \[Convidien\], Masimo Radical-7 \[Irvine\], and SenTec Digital Monitoring System \[Therwil BL\]) and plethysmography (Ambu \[Ballerup, Denmark\] Sleepmate and Perfect Fit 2 \[Dymedix\]). Chest wall and abdominal excursions were recorded using inductance plethysmography (Ambu, Ballerup, Denmark and Sleepmate or Perfect Fit 2, Dymedix, St Paul, MN, USA).

Breathing analysis for apnea utilized careful composite analysis of inductance plethysmography, EEG breathing artifact and visually inspected thoraco-abdominal excursions 2 min before seizure onset (clinical or electrographic, whichever that occurred first). Central apnea (cessation of thoraco-abdominal breathing movements) was defined as ≥1 missed breath without any other explanation (i.e., speech, movement, or intervention), with a minimal duration of 5 s. ICA referred to apnea in NCS, or apnea occurring in the pre-convulsive phase of GCS. PCCA referred to apnea after GCS; we preferred this term to post-ictal central apnea since it could occur after convulsions but before EEG seizure end. Incidences of ICA and PCCA were determined, as well as their durations. Apnea could not be, and was not assessed during tonic or clonic movements, because of invariable artifact presence in breathing channels. A subgroup analysis identified recurrences of ICA and PCCA (in ≥2 seizures).

Hypoxemia was defined as SpO~2~ \< 95% and where baseline SpO~2~ was already \<95% a \>1% drop was considered significant. Oxygen desaturations were classified as mild (SpO2 90--94%), moderate (75--89%), and severe (\<75%). For SpO~2~ evaluation, several time points were considered. Firstly, SpO~2~ was determined at baseline, 2 min pre-ictally as mean SpO~2~ in a 15 s, artifact free epoch. For GCS and NCS, the overall desaturation nadir referred to the lowest SpO~2~ value registered during and up to 3 min after the seizure. To evaluate respiration in the pre-convulsive phase of GCS, an additional desaturation nadir was considered during this phase in patients with ICA.

Presence and duration of PGES ([@B18]) after GCS was determined by a validated automated EEG suppression detection tool ([@B19]), and supplemented with visual analysis by two epilepsy neurophysiologists when the tool gave no solution. Presence and duration of post-ictal EEG burst suppression were also determined. Combined PGES and burst suppression comprised EEG "recovery" duration.

Statistical Analysis
--------------------

Statistical analyses were conducted using SPSS (version 24; IBM Corp, Armol, NY, USA) and SAS for Windows 9.4 (SAS Institute Inc., NC, USA). Summary statistics were reported as mean ± standard deviation (SD; median, range). Relative risk (RR) for the primary outcome of ICA and PCCA at a seizure level was assessed by Generalized Estimating Equation (GEE) with same subject exchangeable correlation. All variables with a *p* \< 0.20 in a univariate analysis were included in a multivariate Poisson GEE regression ([@B20]). Variables related to ICA and PCCA durations were determined using Cox Regression with robust sandwich covariance estimation ([@B21]). Lastly, recurrence of ICA and PCCA for each patient with at least two seizures in this data were categorized as binary outcomes and patient-level covariates were included in respective logistic regressions. Corresponding 95% CIs of risk and hazard ratios were generated from these models. The significance level for hypothesis testing was set at *p* \< 0.05.

Results {#s3}
=======

Demographic and Clinical Characteristics
----------------------------------------

Among 218 patients (130 female), 558 seizures met inclusion criteria. Four hundred and twenty-six seizures were previously reported in two different studies ([@B13], [@B14]).

Mean age at study was 40.2 years ± 14.7 (39; 18--77), mean epilepsy duration was 16.6 years ± 13.8 years (1 month−58 years) and mean age at epilepsy onset was 23.5 years ± 17.2 (20; 1 month-69 years). There were 321 NCS (in 128 patients) and 237 GCS (in 137 patients). State was sleep in 239 seizures and wakefulness in 318 seizures. One seizure arose from post-ictal coma in a patient with a seizure cluster.

There were 182 patients (493 seizures) with focal epilepsy and 33 patients (60 seizures) with generalized epilepsy. One patient had both focal and generalized epilepsy (2 seizures). Epilepsy type was unknown in 2 patients (3 seizures) ([Table 1](#T1){ref-type="table"}).

###### 

Patient characteristics.

  ---------------------------------------------------------------------------
                          **Number of seizures**\   **Number of patients**\
                          **(*n* = 558)**           **(*n* = 218)**
  ----------------------- ------------------------- -------------------------
  **SEX**                                           

  Male                    250                       88

  Female                  308                       130

  **EPILEPSY TYPE**                                 

  Generalized             60 (10.8%)                33 (15.1%)

  Focal                   493 (88.3%)               182 (83.5%)

    Temporal              292 (52.3%)               115 (52.8%)

    Frontal               90 (16.1)                 33 (15.1%)

    Multifocal            45 (8.1%)                 15 (6.9%)

    Lateralized           36 (6.5%)                 11 (5%)

    Occipital             11 (2%)                   4 (1.8%)

    Parietal              12 (2.2%)                 2 (0.9%)

    Insular               7 (1.3%)                  2 (0.9%)

  Focal and generalized   2 (0.4%)                  1 (0.55)

  Unknown                 3 (0.5%)                  2 (0.9%)

  **LATERALIZATION**                                

  Right                   169                       70

  Left                    212                       74

  Bilateral               92                        33

  Generalized             60                        33

  Unknown                 23                        7

  Focal and generalized   2                         1
  ---------------------------------------------------------------------------

PGES could be determined in all but one GCS, where electrode artifact prevented accurate interpretation. PGES occurred in 165/236 (69.9%) GCS in 106/136 (77.9%) patients. Mean PGES duration was 38.9 s ± 21.2 (37; 1--169) and mean EEG recovery duration was 85 s ± 107.9 (54; 1--1,091).

Ictal Central Apnea (ICA) Incidence, Duration, and Recurrence
-------------------------------------------------------------

ICA could not be confidently ascertained in 71 seizures, all GCS, due to plethysmographic signal acquisition artifact. ICA occurred in 180/487 (36.9%) seizures in 83/192 (43.2%) patients: 65/166 (39.2%) in GCS and 115/321 (35.8%) in NCS (*p* = 0.960).

ICA preceded EEG seizure onset in 85/180 (47.2%) seizures by 9 s ± 9.5 (7; 1--58). ICA occurred after EEG seizure onset in 74/180 (41.1%) seizures, with a delay of 25.8 s ± 62 (8; 1--436). ICA coincided with EEG seizure onset in the remaining 21/180 (11.7%) seizures ([Figure 1A](#F1){ref-type="fig"}).

![Ictal central apnea (ICA) timing with respect to EEG onset **(A)** and clinical onset **(B)**.](fneur-10-00166-g0001){#F1}

ICA was the sole manifestation in 14/180 (7.8%) seizures. It coincided with clinical onset in 24/166 (14.5%) seizures, started before clinical onset in 102/166 (61.4%), preceding it by 16.3 ± 12.7 s (12; 1--66 s), and started after clinical onset in 40/180 (24.1%) seizures, with a difference of 26.4 s ± 36 (14.5; 1--195) ([Figures 1B](#F1){ref-type="fig"}, [2A,B](#F2){ref-type="fig"}).

![Example of ictal central apnea (ICA). Sensitivity 7 μV, High Frequency Filter: 70 Hz, Time constant: 0.1 s. **(A)** Twelve seconds after the electrographic onset, ICA is noted without any other clinical signs. **(B)** Continuation of ICA, with a total duration of 14 s, followed by breathing resumption. ABD, abdominal; EEG sz onset, electrographic seizure onset; EKG, electrocardiogram; ICA, Ictal central apnea; s, seconds; THOR, thoracic.](fneur-10-00166-g0002){#F2}

Information regarding nadir SpO~2~ in NCS and the pre-convulsive phase of GCS was available in 141/180 (78.3%) seizures with ICA, with a mean value of 87.7% ± 9.4 (91; 46--99).

All 180 seizures with ICA were seen in focal epilepsies, and none in patients with generalized epilepsy. In patients with focal epilepsies ICA was more frequent in temporal lobe epilepsies than extratemporal (*p* = 0.002) but there was no association with laterality (*p* = 0.215). ICA incidence did not show any differences regarding sex (*p* = 0.171) or epilepsy duration (*p* = 0.077) but it was related to older age at study (*p* = 0.004) and older age at epilepsy onset (*p* \< 0.001). ICA was more frequent in seizures arising from sleep than during wakefulness (*p* = 0.013). ICA was not related to PGES or PCCA and did not affect PGES, EEG recovery, hypoxemia or PCCA durations or SpO2 nadir in GCS (*p* \> 0.050) ([Table 2](#T2){ref-type="table"}).

###### 

ICA incidence and seizure characteristics.

                                                                                                       **Univariate analysis**   **Multivariate analysis**   
  --------------------------------------------------------------------- -------------- --------------- ------------------------- --------------------------- -------
  Sex                                                                                                  0.171                     0.87 (0.64--1.18)           0.383
    Male                                                                129            91                                                                    
    Female                                                              178            89                                                                    
  Age at study (y.o)                                                    38.2 ± 14.9    44.5 ± 15.3     0.004                     --                          --
  Age at epilepsy onset (y)                                             18.7 ± 16.4    28 ± 17.1       \<0.001                   1.01 (1.00--1.02)           0.222
  Epilepsy duration (y)                                                 19.5 ± 14.1    16.6 ± 14.1     0.077                     0.98 (0.97--1.00)           0.608
  Epilepsy type                                                                                        --                        --                          --
    Generalized                                                         51             0                                                                     
    Focal                                                               251            180                                                                   
  Epileptogenic zone                                                                                   0.002                     0.58 (0.37--0.90)           0.015
    Extratemporal                                                       133            40                                                                    
    Temporal                                                            118            140                                                                   
  Lateralization                                                                                       0.215                     --                          --
    Left                                                                90             94                                                                    
    Right                                                               99             52                                                                    
  State                                                                                                0.013                     1.33 (1.08--1.64)           0.008
    Awake                                                               191            92                                                                    
    Asleep                                                              116            87                                                                    
  Semiology                                                                                                                                                  
    GCS                                                                 101            65              0.960                     --                          --
    NCS                                                                 206            115                                                                   
  PGES[^a^](#TN1){ref-type="table-fn"}                                                                 0.308                     --                          --
    No                                                                  90             12                                                                    
    Yes                                                                 70             53                                                                    
  PGES duration[^a^](#TN1){ref-type="table-fn"} (s)                     36.3 ± 15.8    43.3 ± 29.7     0.618                     --                          --
  EEG recovery duration (s)                                             70.9 ± 61.8    106.2 ± 162.1   0.512                     --                          --
  Recovery time to mild hypoxemia[^a^](#TN1){ref-type="table-fn"} (s)   41.8 ± 31.9    48.5 ± 46       0.903                     --                          --
  Total hypoxemia duration[^a^](#TN1){ref-type="table-fn"} (s)          147.5 ± 70.4   149.9 ± 56.2    0.953                     --                          --
  SpO~2~ nadir[^a^](#TN1){ref-type="table-fn"} (%)                      59.5 ± 14.4    58.3 ± 13.2     0.576                     --                          --
  PCCA[^a^](#TN1){ref-type="table-fn"}                                                                 0.785                     --                          --
    No                                                                  79             49                                                                    
    Yes                                                                 18             14                                                                    
  PCCA duration[^a^](#TN1){ref-type="table-fn"} (s)                     8 ± 3.3        10.4 ± 6.7      0.509                     --                          --

*GCS, generalized convulsive seizures; NCS, non-convulsive seizures; PCCA, post-convulsive central apnea; PGES, post-ictal generalized electroencephalographic suppression; SpO~2~, peripheral capillary oxygen saturation; y, years y.o, years old*.

*Analyzed only in GCS*.

After multivariate analysis, sleep state was related to presence of ICA \[RR 1.326, CI95% (1.075--1.637), *p* = 0.008\] whereas extratemporal epilepsy was related to lower incidence of ICA \[RR 0.579, CI 95% (0.373--0.900), *p* = 0.015\].

Mean ICA duration was 20.9 s ± 17.5 (14; 5--97 s) and was longer in patients with NCS without subsequent GCS than those with subsequent GCS \[HR 2.276; CI 95% (1.565--3.311), *p* \< 0.001\] and in temporal lobe epilepsy compared to extratemporal \[HR 1.753, CI 95% (1.065--2.885), *p* = 0.027\]. ICA duration did not correlate with awake/sleep state at seizure onset (*p* \> 0.050). Longer ICA duration was associated with lower SpO~2~ nadir during the NCS phase of seizures \[HR 1.098, CI 95% (1.064--1.133), *p* \< 0.001\] and longer EEG recovery duration \[HR 1.002, CI95% (1.001--1.003), *p* = 0.003\]. ICA duration did not significantly correlate with hypoxemia duration, PGES duration, or SpO~2~ nadir in GCS.

Mean number of seizures per patient was 2.6 ± 1.7 (2; 1--8). In the total sample, 92/218 (42.2%) patients either had only one seizure, or only one analyzable seizure for ICA. The remaining 126/218 (57.8%) patients had recurrent seizures and comment on ICA could be made. ICA occurred in 60/126 (47.6%) patients, and recurred in 45/60 (75%) of the patients. No clinical characteristics (age, age at epilepsy onset, epilepsy duration, sex, and epileptogenic zone) were related to ICA recurrence (*p* \> 0.05).

### Clinical Case 1-Prolonged ICA and near-SUDEP

A 36 year-old right handed man with intractable right temporal lobe epilepsy of unknown etiology since the age of nine was enrolled into the study. His seizure semiology consisted of psychic aura followed by auditory aura with impaired awareness, and rare secondarily generalization. The last generalized convulsion had occurred 4 years before the admission. He had co-morbid depression. Previous antiepileptic drugs (AEDs) were carbamazepine, phenytoin, valproic acid and zonisamide. At admission for presurgical evaluation he was on oxcarbazepine 1,800 mg/day. Physical and neurological examinations were normal. Brain MRI was normal and the interictal PET scan showed bilateral mesial temporal hypometabolism, more pronounced on the right. Interictal recordings showed right temporal sharp waves (maximum at T8\>F8). Retrospective review of older (non-study) VEEG records revealed a near-SUDEP incident (not included in the above analysis). The patient had 4 seizures during that admission. The first one, was a brief (\<10 s duration auditory aura). The second and third seizures, were brief auras with rapid secondarily generalization, one arising from wakefulness and the other one arising from sleep. No comment about presence of ICA could be made on those seizures due to lack of plethysmography and rapid secondary generalization. No PCCA was noted in any of the GCS and regular breathing resumed immediately after clinical seizure end. These GCS occurred within 12 h of the fourth and last seizure. This was an apneic seizure with impaired awareness, and respiratory arrest lasting for 285 s, as evidenced by video analysis and oxygen desaturation. After a period of several shallow breaths, breathing finally resumed normally 311 s after seizure onset. Ictal EEG showed rhythmic alpha activity arising over the right antero-mesial temporal lobe with bilateral spread. No alteration in heart rhythm was noted apart from tachycardia. The patient was repositioned, oxygen administered, and ventilated with a face mask. He later underwent invasive evaluation, had further seizures without apnea, and a right temporal lobectomy in 2016 which resulted in seizure freedom (Engel Class 1, \[\>2 years\]) [Video 1](#s8){ref-type="supplementary-material"}.

Post-convulsive Central Apnea (PCCA) Incidence, Duration, and Recurrence
------------------------------------------------------------------------

Presence of PCCA could not be confidently ascertained in 9/237 (3.8%) GCS in 3/137 (2.2%) patients due to movement artifact. PCCA was present in 41/228 (18%) of GCS in 30/134 (22.4%) patients.

In 24/41 (58.65%) seizures (in 19 patients), PCCA was observed without EEG seizure. In 14/41 (34.1%) seizures (in 12 patients), PCCA occurred with ongoing EEG seizure activity. In 3 seizures (in 3 patients) PCCA recurred in the same seizure, occurring initially with EEG seizure discharges and then after 1--2 breaths, recurring without accompanying seizure discharge([Figures 3A,B](#F3){ref-type="fig"}). In 13 seizures (in 11 patients), PCCA immediately followed clinical seizure end. In 25 seizures (in 20 patients), "delayed" PCCA occurred several breaths after clinical seizure end.

![Example of post-convulsive central apnea (PCCA). Sensitivity 20 μV, High Frequency Filter: 70 Hz, Time constant: 0.1 s. **(A)**. After the end of convulsive phase, the patient is apneic for 7 s. After the electrographic end, there are 2 noticeable breaths which are followed by another brief apnea. Lastly, regular breathing resumes. **(B)** Continuation from **(A)**, regular breathing continues. ABD, abdominal; Clinical sz end, end of clinical seizure. EEG sz end, electrographic seizure end; EKG, electrocardiogram; PCCA, post-convulsive central apnea; s, seconds; THOR, thoracic.](fneur-10-00166-g0003){#F3}

PCCA was more frequent in women than in men (*p* = 0.004) and occurred more often in generalized than focal epilepsies (*p* = 0.016). In focal epilepsy, it was more frequently seen in extratemporal than temporal (*p* = 0.020) patients, but there was no relationship with lateralization (*p* = 0.148). PCCA was unrelated to age at study or epilepsy onset, epilepsy duration and awake or sleep states (*p* \> 0.050). Whereas, ICA presence was not related to PCCA occurrence, PCCA was significantly associated with longer ICA duration (*p* = 0.001).

Presence of PCCA was not related to PGES duration, and was not associated with EEG recovery duration and total hypoxemia duration (*p* \> 0.050). However, PCCA was associated with longer SpO~2~ recovery times to mild hypoxemia (\>90%). \[RR 1.01, CI95% (1.003--1.017), *p* = 0.003\] ([Table 3](#T3){ref-type="table"}).

###### 

PCCA incidence and seizure characteristics.

                                                                                                       **Univariate analysis**   **Multivariate analysis**   
  --------------------------------------------------------------------- --------------- -------------- ------------------------- --------------------------- ---------
  Sex                                                                                                  0.004                     11.29 (4.5--28.34)          \<0.001
  Male                                                                  103             10                                                                   
  Female                                                                84              31                                                                   
  Age at study (yo)                                                     37.7 ± 13.7     34.6 ± 14      0.267                     --                          --
  Age at epilepsy onset                                                 20.2 ± 17.2     19.5 ± 10.7    0.774                     --                          --
  Epilepsy duration (y)                                                 17.4 ± 12.1     14.9 ± 11.9    0.323                     --                          --
  Epilepsy type                                                                                        0.016                     --                          --
    Generalized                                                         25              11                                                                   
    Focal                                                               160             27                                                                   
  Epileptogenic zone                                                                                   0.020                     4.48 (1.02--19.59)          0.046
    Extratemporal                                                       64              18                                                                   
    Temporal                                                            96              9                                                                    
  Lateralization                                                                                       0.148                     --                          --
    Left                                                                63              14                                                                   
    Right                                                               52              4                                                                    
  State                                                                                                0.738                     --                          --
    Awake                                                               97              20                                                                   
    Asleep                                                              90              20                                                                   
  ICA duration                                                          11.96 ± 5.75    18.6 ± 11.5    0.001                     1.14 (1.05--1.25)           0.001
  PGES[^a^](#TN2){ref-type="table-fn"}                                                                 0.091                     0.27 (0.16--0.47)           \<0.001
     No                                                                 60              8                                                                    
    Yes                                                                 126             33                                                                   
  PGES duration[^a^](#TN2){ref-type="table-fn"}(s)                      38.7 ± 18.9     39.5 ± 27.8    0.804                     --                          --
  EEG recovery duration[^a^](#TN2){ref-type="table-fn"} (s)             86.4 ± 80       83.5 ± 184.4   0.876                     --                          --
  Recovery time to mild hypoxemia[^a^](#TN2){ref-type="table-fn"} (s)   36.2 ± 31.3     58.3 ± 42      0.003                     --                          --
  Total hypoxemia duration[^a^](#TN2){ref-type="table-fn"} (s)          144.86 ± 70.3   139.1 ± 40.9   0.301                     --                          --
  SpO~2~ nadir[^a^](#TN2){ref-type="table-fn"}                          60.76 ± 13.8    58.3 ± 16      0.555                     --                          --

*GCS, generalized convulsive seizures; ICA, ictal central apnea; NCS, non-convulsive seizures; PCCA, post-convulsive central apnea; PGES, post-ictal generalized electroencephalographic suppression; SpO~2~, peripheral capillary oxygen saturation; y, years; y.o, years old*.

*Analyzed only in GCS*.

After multivariate regression analysis, female sex \[RR 11.297, CI 95% (4.50--28.34), *p* \< 0.001\] and ICA duration \[RR 1.149 CI 95% (1.053--1.254), *p* = 0.001\] were related to PCCA, whereas absence of PGES was related to absence of PCCA \[RR = 0.274, CI 95% (0.159--0.471), *p* \< 0.001\].

Mean PCCA duration was 8.9 s ± 4.9 (5--32). PCCA duration was longer in males \[HR 1.844, CI 95% (1.06--3.19), *p* = 0.003\]. Epilepsy type, awake/sleep state did not influence PCCA occurrence. PCCA duration did not correlate with age, epilepsy duration, PGES duration, EEG recovery, hypoxemia duration, or time to recovery to mild hypoxemia (*p* \> 0.050).

Mean number of GCS per patient was 1.7 ± 1 (1; 1--5). In patients with GCS, 77/137 (56.2%) had only one GCS and the remaining 60/137 (47.8%) had two or more GCS. In the group of patients with repeated GCS, comment on PCCA could be made on 57/60 (95%) patients. PCCA was seen in 17/57 (29.8%). In 9/17 (52.9%) patients, PCCA was recurrent.

### Clinical Case 2-Prolonged PCCA and near-SUDEP

A 15 year-old right handed girl with epilepsy since age 5 years was admitted for evaluation. She was not an enrolled study patient. Seizures occurred once or twice a month and lasted up to two with whole body sensory aura (tingling) followed by oral automatisms with impaired awareness. This was rarely followed by secondary generalized convulsions lasting 1--2 min. On several occasions, paramedics were summoned as an emergency because of cyanosis and unresponsiveness after generalized convulsions. On admission she was on lamotrigine 200 mg/day and levetiracetam 3,000 mg/day, having previously failed multiple other AEDS. She had no epilepsy risk factors and no family history of epilepsy. Her physical and neurological examinations were normal. Epilepsy protocol MRI brain scans were normal on two occasions. Inter-ictal brain FDG-PET showed focal hypometabolism in the anterior left temporal lobe tip. Non--invasive VEEG monitoring showed left temporal sharp waves, maximum at F7/T7/FT9. Four habitual clinical seizures were recorded without secondarily generalization. EEG onsets were left hemispheric but not further localizable.

She underwent invasive EEG monitoring for better localization of the epileptogenic zone. A left subdural grid (8 × 6) was implanted along with strips covering the left orbitofrontal, superior temporal, inferior temporal regions, as well as left anterior-anterior, anterior-middle and anterior-posterior temporal, left middle temporal, left middle-middle, and middle-posterior. A left anterior temporal seizure was recorded, with typical automatisms and impaired awareness, right face clonic movements, and a secondary generalized tonic clonic seizure. After clinical seizure end, the patient was immediately apneic (as evidenced by video analysis, cyanosis, and severe O~2~ desaturation) for 126 s, followed by an isolated breath. A second period of apnea/hypopnea was then seen until regular breathing pattern resumed a total of 187 s after clinical seizure end. EEG seizure discharges were seen up to 25 s after clinical seizure end. Thirty nine seconds after clinical seizure end, there was concurrent progressive bradycardia followed by 10 s of asystole. Cardiac rhythm resumed, with a pattern of bradycardia and normal sinus rhythm, for 75 s, after which EKG signal was lost, but pulse artifact was evident on EEG. EEG suppression duration (all invasive electrodes), was \~254 s. During the episode, there was repeated tactile nursing intervention. Further, her head was re-positioned and O2 administered. No active resuscitation measures were performed. Due to continuing seizures, the patient underwent responsive neurostimulation (RNS® System) and was temporarily seizure free for 3 years, until recent recurrence of focal seizures at last follow up [Video 2](#s8){ref-type="supplementary-material"}.

Discussion {#s4}
==========

In this study we summarize incidence and risk factors for both ICA and PCCA. Additionally, we describe two near-SUDEP instances of prolonged ICA and PCCA, respectively.

ICA incidence in our study (43.2%), on a larger number of patients, was similar to those previously reported ([@B10], [@B13]). Consistent with our previous reports, ICA was not observed in patients with generalized epilepsy, and was more frequent in patients with temporal rather than extratemporal epilepsy ([@B13], [@B14]). ICA preceded other clinical signs in the vast majority of seizures and in almost half of them, also preceded EEG seizure onset. The observation of ICA being an exclusive feature for focal epilepsies, and especially in those from the temporal lobe, is consistent with previous human stimulation studies pointing out the amygdala, hippocampus, and mesial temporal pole, regardless of lateralization, as the symptomatogenic zone for ICA ([@B11], [@B13], [@B22]). The absence of ICA in the GCS of generalized epilepsy is in large part due to immediate or rapid generalization where breathing compromise may be partly or wholly due to generalized muscle tonicity that includes respiratory musculature, rather than solely due to unequivocal central apnea. However, we cannot be sure that these patients truly do not have ICA.

Unlike previous publications ([@B13]), where no differences between awake/sleep states at seizure onset were found, in this more robustly powered study, ICA occurred more frequently in seizures arising from sleep. One possible explanation is that ICA is easier to detect in the sleep state, where acquisition artifact is less prevalent. However, awake recordings were not disproportionately excluded because of artifact and such disparities can be explained by physiological differences in breathing control during sleep and wakefulness ([@B23]). Breathing is under automatic control through multiple pontomedullary nuclei, the pre-Bötzinger complex (pre-BötC) comprising the main rhythm generator ([@B24]). Cortical and subcortical structures, such as thalamus, hypothalamus, amygdalo-hippocampal complex, cerebellum, and mesencephalic nuclei relay to pontomedullary respiratory centers and along with peripheral sensory feedback, modulate breathing output ([@B25]). There is increased evidence that serotoninergic neurons lying in the midline raphe nuclei play an active role in both arousal and chemoreception ([@B26], [@B27]). These neurons tonically excitate multiple components of the brainstem respiratory network, with interconnections with the pre-BötC, and also act as central chemosensors, detecting changes in tissue CO~2~/H^+^ modulating the aforementioned tonic excitatory drive to adjust ventilation accordingly ([@B28]). Mice with genetically deleted medullary serotoninergic neurons lack any arousal response to inhalation of CO~2~ but have normal arousal responses to other stimuli such as hypoxia, sound and air puffs ([@B26]). Moreover, the activity of medullary raphe serotoninergic neurons is highest during wakefulness and absent during REM sleep ([@B28]). Most SUDEP cases occur at night, and in the MORTEMUS study this was true in the majority of monitored cases ([@B5]) animal studies reveal brainstem serotoninergic dysfunction during and after seizures, with decreased firing of the medullary raphe neurons during the ictal and post-ictal periods ([@B29]). Therefore, in the setting of a potentially dysfunctional serotoninergic network in epileptic patients, sleep would constitute a vulnerable period for breathing disturbances ([@B30]).

The near-SUDEP case with prolonged ICA, in whom breathing resumed after seizure end raises a number of interesting issues. First, it seems possible that unobserved and in the absence of active intervention, the outcome could have been fatal. This supports the contention that prolonged ICA is dangerous and potentially lethal. Second, the near-fatal seizure episode may be more akin to focal status epilepticus, and supports the view that the latter cannot be excluded in at-home, unobserved deaths that are usually labeled SUDEP ([@B31]). Revisiting SUDEP definition (which mandates exclusion of status epilepticus) may be necessary. The episode mimics a sheep model of status epilepticus and apneic death ([@B32]). Third, seizure termination and resumption of breathing with seizure end, suggest that ICA is driven by seizure discharge (likely in the mesial temporal structures), rather than other mechanisms ([@B13]). Finally, why the majority of ICA instance are self-terminating and some become prolonged, is unresolved, but may reflect the consequences of damage caused by early onset, long-standing epilepsy, and frequent GCS to key breathing control sites (amygdala, hippocampus, dorsal thalamus, anterior cingulate, ventrolateral medulla etc.) ([@B33]--[@B35]), rendering greater susceptibility to exaggerated apneic responses.

PCCA incidence (22.4%) was almost half of ICA incidence, more frequently observed in female subjects (although more likely to be longer in male patients), and commoner in those with longer ICA duration. In contrast to ICA, PCCA was observed in both patients with focal, and generalized epilepsy. These differences suggest differing pathophysiologies ([@B14]). Whereas, ICA appears to be a semiological phenomenon most often resulting from seizure activity in the amygdalo-hippocampal complex, PCCA most likely results from seizure spread to the brainstem during GCS, regardless of epileptogenic zone ([@B36]). Breathing cessation may be derived either from active depolarization and activation of crucial breathing centers that generate apneic responses, such as the periaqueductal gray ([@B37], [@B38]), or disruption of the normal functioning of rhythm-generating neurons and its intricate network, leading to breathing cessation ([@B39]). This is consistent with animal models of SUDEP showing post-ictal depolarization in dorsal medulla ([@B40]), in which apnea and PGES precede cardiac arrest, and resemble the clinical phenotype of monitored SUDEP patients in the MORTEMUS study ([@B5]). Human neuroimaging and neuropathological studies have shown damage in key brainstem structures that modulate breathing, such as the medullary raphe and ventrolateral medulla, in SUDEP and high SUDEP-risk patients ([@B33], [@B41], [@B42]).

In our study, ICA duration conferred higher risk for PCCA and was related to lower SpO~2~ nadirs in the pre-convulsive phase. This may indicate greater hypoxemia induced brainstem compromise, leading to PCCA. Seizure induced focal brainstem hypoxia, due to vasospasm, has been described in animal models and posited as a potential mechanism for SUDEP ([@B43]--[@B45]). Moreover, we found that the presence of PCCA was related to longer hypoxemia recovery times (SpO~2~ \> 90%). Although causality could not be established, longer hypoxemia recovery times may be a consequence of PCCA. However, PCCA duration itself, was not related to hypoxemia severity or duration. PCCA durations were typically short, and hypoxemia severity may be more related to GCS severity, although PCCA impact on hypoxemia may become independently important in instances of prolonged PCCA.

Although PCCA occurred preferentially in women, its duration was longer in men, consistent with the SUDEP phenotype ([@B2]). Sex differences in breathing function and the protective role of estrogens in respiratory diseases may explain these findings ([@B46]--[@B48]), since differences in epilepsy phenotype do not explain these differences. As with ICA, duration rather than presence, may primarily influence SUDEP risk in PCCA.

PGES is a frequent finding in GCS, particularly in those arising from sleep and is related to the symmetric tonic phase, postictal immobility, lack of early oxygen administration, duration of oxygen desaturation and lower SpO~2~ nadir values ([@B49]--[@B51]). PGES has been postulated as a SUDEP biomarker, especially if prolonged (\>50 s) ([@B18]). Its relationship with ICA or PCCA has not been established, except indirectly through O~2~ desaturation findings ([@B50]). In our study, PCCA was proportionally seen more frequently in seizures with PGES than in seizures without. The pathogenesis of PGES is not well-determined. Cortical neuronal exhaustion or a disruption of ascending inputs after a GCS, or a combination of both, are viable hypotheses. Disruption of ascending pathways such as from the reticular activating system may conceivably prolong the comatose post-ictal state, as well as modulate cortical neuronal activity, and thus, impair the protective behavioral effect of arousal to overcome PCCA ([@B52]).

ICA recurred in 75% of the cases, whereas PCCA recurred in 52.9%. This may further reinforce that ICA is a semiological, and therefore recurrent, phenomenon. However, PCCA seems only slightly less frequent, and may also be semiological rather than probabilistic, although our two case reports suggest that prolonged instances of either, are what potentially determine mortality risk. PCCA instances combined with bradycardia/asystole may be particularly dangerous. Our second clinical case of prolonged PCCA accompanied by asystole, resembles the clinical phenotype described in the MORTEMUS study and in a recent analysis of this cohort in a smaller number of patients ([@B14]). Invasive monitoring did not show ongoing seizure activity that was concurrent with apnea, reinforcing once again, the different pathophysiologies of ICA, and PCCA, with higher likelihood of involvement of subcortical structures, such as the brainstem, in PCCA ([@B53], [@B54]).

Our study has several limitations. First, it is an observational study in a select group of patients (i.e., primarily treatment resistant epilepsy) and does not necessarily reflect seizure phenomenology or SUDEP risk in a treatment responsive population. Detection of ICA was heavily dependent on extent of acquisition artifact, and hence we may have underestimated incidence. Alternatively, postictal immobility after GCS allowed PCCA identification in the majority of cases. Breathing analysis through polygraphic study was limited to thoraco-abdominal movement and pulse oximetry. Thus, additional information on the presence of mixed central/obstructive apneas, is unavailable. Our apnea definition differs from previous literature, which is based on the 10 s sleep-study criterion, and therefore, ICA and PCCA incidence may be overestimated in our study. However, based on our brain stimulation experiments on breathing modulation, where brief stimulation periods result in immediate and brief (\<10 s) apneas, we believe our definition is both accurate and sensitive ([@B12], [@B22]). Our conclusions are based on a relatively small group of number seizures in the primary generalized epilepsy group compared to patients with focal epilepsy. Lastly, our study was based on surface EEG and persistence of intracranial seizure in deep, apnea causing structures ([@B12]) cannot be completely excluded in patients with PCCA. However, Case 2 above, along with a previous case reported in literature, suggest that apnea in epileptic patients can occur in the absence of electrographic seizure ([@B53]).

Conclusions {#s5}
===========

Peri-ictal central apnea takes two main forms, as ICA or PCCA. ICA incidence is almost twice PCCA incidence and is only seen in focal epilepsies, suggesting different pathophysiologies. Both ICA and PCCA may be recurrent, but prolonged instances leading to SUDEP and near-SUDEP may be probabilistic instances. Prolonged ICA is related to presence of PCCA, possibly due to greater effect of ICA-induced hypoxemia on brainstem function. Absence of PCCA is associated with absence of PGES, suggesting that PCCA presence directly correlates with GCS severity. Alternatively, brainstem structures responsible for arousal and breathing may obviate PGES occurrence. Apnea preceding both EEG as well as clinical seizure onset in a substantial number of patients suggests that plethysmographic respiratory monitoring in regular clinical practice may have seizure detection value. Moreover, such monitoring may facilitate detection of prolonged ICA and PCCA, thus allowing SUDEP risk quantification although further evidence is required to confirm this. Both prolonged ICA and PCCA may contribute to SUDEP. Further prospective cohort studies are needed to validate these hypotheses.
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